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Abstract 
Naringin is one of the citrus-derived flavonoids that have been reported for its 
antihyperglycemic, antihyperlipidemic and antioxidant properties. Although its usefulness as 
nutraceutical in the management of diabetes has been reported, there is a dearth of 
information on involvement of lipid-associated protein antioxidant like paraoxonase in its 
antidiabetic activity. In order to investigate this, high fat-low streptozocin model of type 2 
diabetic rats were treated daily with 50mg/kg, 100mg/kg and 200mg/kg naringin orally for 
21days. The levels of plasma insulin and dipeptidyl peptidase-4 (DPP IV) were determined 
using enzyme-linked immunosorbent assay while other biomarkers of T2DM, activity of 
paraoxonase and lipid profile were assayed spectrophotometrically. The levels of expression 
of hepatic 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), scavenger receptor class 
B member 1 (SCARB1), Aryl Hydrocarbon Receptor (AhR), Lipoprotein Lipase (LIPL), and 
Lecithin—cholesterol acyltransferase (LCAT) were assessed using reverse transcriptase 
polymerase chain reaction technique. Naringin treatment resulted in a significant (p<0.05) 
decrease in levels of plasma glucose, insulin, free fatty acid, amylase and DPP IV. Naringin 
treatment was also associated with a significant (p<0.05) decrease in the levels of cholesterol 
and triglyceride in the plasma and liver in the dose-dependent pattern. In the liver, the activity 
of carnitine palmitoyltransferase was significantly increased (p<0.05) while the expression of 
HMGCR was only significantly (p<0.05) reduced by 200mg/Kg naringin treatment. 
Meanwhile, SCARB1, AhR, LIPL and LCAT were significantly (p<0.05) upregulated by 
naringin treatment. Although T2DM resulted in increased activities of PON in the plasma, 
HDL and VLDL, a decrease in activity was observed in the liver. These alterations in PON 
activities were however significantly (p<0.05) reversed by naringin treatment. These results 
showed that PON is involved in the antidiabetic action of naringin. 
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